Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01856530 · ClinicalTrials.gov registry record · Phase 1
Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder
A Phase 1 study of Social Anxiety Disorder, sponsored by Stefan G. Hofmann.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01856530: Completed Phase 1 study of Social Anxiety Disorder, sponsored by Stefan G. Hofmann.
NCT01856530 is a Phase 1 study of Social Anxiety Disorder that has completed, run by Stefan G. Hofmann. The registered enrollment target is 60 participants, below the 158-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01856530, a Phase 1 study of Social Anxiety Disorder, has completed, sponsored by Stefan G. Hofmann.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about how the hormone, oxytocin, impacts social behavior in terms of cooperation with others, attention processing, and reward processing, among patients with social anxiety disorder. Based on available research, the investigators predict that in patients with social anxiety disorder, oxytocin will improve social cooperation during an online ball-tossing game called Cyberball, reduce attention toward socially threatening cues during a dot-probe task, and lead to greater willingness to work for monetary rewards for others rather than themselves during an effort expenditure task.
Primary Outcome
The outcome measure involved difference scores in the number of balls tossed to Player 1 between two conditions of the task. Across both conditions, the participant (always assigned as "Player 2") played with 3 other on-line players in real time. In Condition 1, Player 1 was programmed to toss on average 70% of his balls to the participant. In Condition 2, Player 1's behavior switched such that he was programmed to toss on average only 10% of his balls to the participant. The data reported below
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oxytocin
Study Locations (1)
Massachusetts
- Center for Anxiety and Related Disorders at Boston University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
What the finished NCT01856530 record still lists
NCT01856530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 158-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01856530 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01856530 about?
NCT01856530 is a clinical study titled "Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder". The purpose of this study is to learn more about how the hormone, oxytocin, impacts social behavior in terms of cooperation with others, attention processing, and reward processing, among patients with social anxiety disorder. Based on available research, the investigators predict that in patients w...
What is the current status of trial NCT01856530?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2012-07. Estimated completion is 2013-08.
What conditions does trial NCT01856530 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT01856530?
The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).
Who is sponsoring clinical trial NCT01856530?
This trial is sponsored by Stefan G. Hofmann, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01856530 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01856530's enrollment target sits among peer trials
60 21st of 32 higher than 8 of 32 other Social Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Social Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
-
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
RECRUITING · Phase 2
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
RECRUITING · NA
-
Targeting Social Function in Anxiety and Eating Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia